Re: ZHCLF trading
in response to
by
posted on
Feb 08, 2021 09:39AM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
Is ZCC is a long way off from topline results from where it now stands for it to be a buyout candidate? Don't know!
ClinicalTrials.gov Identifier: NCT03901469
| Official Title: | A Phase 2 Study of ZEN003694 in Combination With Talazoparib in Patients With Triple-Negative Breast Cancer |
| Actual Study Start Date : | June 26, 2019 |
| Estimated Primary Completion Date : | September 2021 |
| Estimated Study Completion Date : | January 2022 |
Koo